Francesca Palandri, MD, discusses research needed to clarify the role of predictive markers for ruxolitinib response in myelofibrosis.
Francesca Palandri, MD
Advertisement
Articles by Francesca Palandri, MD
Francesca Palandri, MD, shares SVR35 rates with momelotinib vs ruxolitinib across patient subgroups in the anemic subpopulation of SIMPLIFY-1.
Advertisement
Latest Updated Articles
Dr Palandri on Outcomes With Momelotinib in Myelofibrosis Per Dual SVR35 and Transfusion IndependencePublished: June 27th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5